Rodman & Renshaw Initiates Nkarta(NKTX.US) With Buy Rating, Announces Target Price $14
Mizuho Securities Maintains Nkarta(NKTX.US) With Buy Rating, Cuts Target Price to $20
A Quick Look at Today's Ratings for Nkarta(NKTX.US), With a Forecast Between $13 to $22
HC Wainwright & Co. Maintains Buy on Nkarta, Lowers Price Target to $22
A Quick Look at Today's Ratings for Nkarta(NKTX.US), With a Forecast Between $13 to $22
Nkarta Price Target Maintained With a $13.00/Share by Needham
Nkarta Analyst Ratings
Raymond James Upgrades Nkarta to Strong Buy, Maintains Price Target to $16
TD Cowen Remains a Buy on Nkarta (NKTX)
Nkarta Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target
H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $23
Buy Rating Confirmed: Expanding Potential of Nkarta's NKX019 in SLE Treatment
Needham Reiterates Buy on Nkarta, Maintains $13 Price Target
Nkarta Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Nkarta, Maintains $23 Price Target
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Needham: Maintaining the Nkarta (NKTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $15.00 to $13.00.
Nkarta Analyst Ratings
Nkarta Analyst Ratings